Previous 10 | Next 10 |
2023-12-07 15:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today we're highlighting November 2023 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ...
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares ...
VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ia...
2023-11-30 01:52:55 ET More on Xenon Pharma Xenon: MDD Data Provides Rationale For XEN1101 Advancement Towards FOS Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip Xenon Pharmaceuticals announces proposed public offering Xenon says mid-stage trial...
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common...
2023-11-29 16:08:26 ET More on Xenon Pharma Xenon: MDD Data Provides Rationale For XEN1101 Advancement Towards FOS Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript Xenon says mid-s...
2023-11-28 13:49:13 ET Summary Xenon Pharmaceuticals Inc.'s XEN1101 is being advanced in two identical phase 3 studies known as X-TOLE2 and X-TOLE3 for patients with focal onset seizure; Completion of recruitment for XTOLE-2 expected end of 2024. The global epilepsy market size wi...
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is one of today's top gainers. The company's shares have moved 2.07% on the day to $31.51. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canad...
2023-11-27 07:38:21 ET More on Xenon Pharma Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An ...
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evalu...
News, Short Squeeze, Breakout and More Instantly...
Xenon Pharmaceuticals Inc. Company Name:
XENE Stock Symbol:
NASDAQ Market:
Xenon Pharmaceuticals Inc. Website:
2024-05-15 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azet...
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV....